

## HR 5590

Opioid Addiction Action Plan Act

**Congress:** 115 (2017–2019, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Apr 24, 2018

**Current Status:** Received in the Senate and Read twice and referred to the Committee on Finance.

**Latest Action:** Received in the Senate and Read twice and referred to the Committee on Finance. (Jun 20, 2018)

**Official Text:** <https://www.congress.gov/bill/115th-congress/house-bill/5590>

### Sponsor

**Name:** Rep. Kinzinger, Adam [R-IL-16]

**Party:** Republican • **State:** IL • **Chamber:** House

### Cosponsors (6 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Clarke, Yvette D. [D-NY-9]	D · NY		Apr 24, 2018
Rep. Davis, Danny K. [D-IL-7]	D · IL		Apr 24, 2018
Rep. LaHood, Darin [R-IL-18]	R · IL		Apr 24, 2018
Rep. Blackburn, Marsha [R-TN-7]	R · TN		May 17, 2018
Rep. Walden, Greg [R-OR-2]	R · OR		May 25, 2018
Rep. Mitchell, Paul [R-MI-10]	R · MI		Jun 8, 2018

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Reported By	Jun 12, 2018
Finance Committee	Senate	Referred To	Jun 20, 2018
Ways and Means Committee	House	Referred to	May 1, 2018

### Subjects & Policy Tags

**Policy Area:**

Health

### Related Bills

Bill	Relationship	Last Action
115 HR 6	Related bill	Oct 24, 2018: Became Public Law No: 115-271.
115 S 2769	Related bill	Apr 26, 2018: Read twice and referred to the Committee on Finance.

## **Opioid Addiction Action Plan Act**

(Sec. 2) This bill requires the Centers for Medicare & Medicaid Services (CMS) to develop an action plan to provide recommendations on changes to the Medicare and Medicaid programs to enhance: (1) the treatment and prevention of opioid addiction, and (2) the coverage and payment of medication-assisted treatment for opioid addiction. The CMS must convene a stakeholder meeting to solicit public comment on the action plan.

The CMS must also publish a report that includes an evaluation of price trends for opioid overdose-reversal drugs (e.g., naloxone) and recommendations on ways to lower consumer prices for such drugs.

### **Actions Timeline**

---

- **Jun 20, 2018:** Received in the Senate and Read twice and referred to the Committee on Finance.
- **Jun 19, 2018:** Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
- **Jun 19, 2018:** Considered under suspension of the rules. (consideration: CR H5247-5249)
- **Jun 19, 2018:** DEBATE - The House proceeded with forty minutes of debate on H.R. 5590.
- **Jun 19, 2018:** Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5247-5248)
- **Jun 19, 2018:** On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5247-5248)
- **Jun 19, 2018:** Motion to reconsider laid on the table Agreed to without objection.
- **Jun 12, 2018:** Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 115-746, Part I.
- **Jun 12, 2018:** Committee on Ways and Means discharged.
- **Jun 12, 2018:** Placed on the Union Calendar, Calendar No. 580.
- **May 17, 2018:** Committee Consideration and Mark-up Session Held.
- **May 17, 2018:** Ordered to be Reported (Amended) by Voice Vote.
- **May 1, 2018:** Referred to the Subcommittee on Health.
- **Apr 24, 2018:** Introduced in House
- **Apr 24, 2018:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.